Disease/Infection News

RSS

Antibiotic resistance: Theme for next Uppsala Health Summit

The theme for the next Uppsala Health Summit, to be held in Uppsala on 2-3 June 2015, is antibiotic resistance -- one of the biggest global health challenges of our day.

2 Dec 2014

Researchers identify infection control gaps as major culprit in spread of MERS-CoV

Little is known about the often fatal virus known as Middle East respiratory syndrome coronavirus (MERS-CoV), but researchers have identified gaps in infection control as a major culprit in all eleven published cases involving healthcare-associated transmission of the virus.

2 Dec 2014

Mylan, CAS to raise funds and awareness for people living with HIV/AIDS

Mylan Inc. and the Canadian AIDS Society (CAS) today announced a joint initiative to raise funds and awareness for Canadians and people worldwide who are living with or at risk of HIV/AIDS.

2 Dec 2014

SIM physicians available to speak on Ebola epidemic ahead of International Volunteer Day

Two SIM USA physicians — one a long-term veteran and the second a new, short-term volunteer — are headed to Ebola-stricken West Africa and available to speak this week in advance of International Volunteer Day, Dec. 5, on a variety of topics related to the outbreak, the healthcare crisis in the region, and the role and need for volunteers.

1 Dec 2014

Mylan enters into agreement with Gilead Sciences to manufacture, distribute Tenofovir Alafenamide

Mylan Inc. today announced that its subsidiary Mylan Laboratories Limited has entered into an agreement with Gilead Sciences, Inc. under which Mylan has licensed the non-exclusive rights to manufacture and distribute Tenofovir Alafenamide (TAF) as both a single agent product and in combination with other drugs.

1 Dec 2014

Cepheid gets FDA clearance to market Xpert Norovirus

Cepheid today announced it has received clearance from the U.S. Food & Drug Administration to market Xpert Norovirus, a qualitative in vitro diagnostic test for expeditious identification and differentiation of Noroviruses genogroup I (GI) and genogroup II (GII).

1 Dec 2014

Predictive model provides information for treating 20% of human diseases

The analysis of drugs, natural products, and chemical substances found in the environment allows the identification of the chemical fragments responsible for a therapeutic or deleterious effect on human health.

1 Dec 2014

Leading experts to discuss specific strategies to combat Ebola

Where do we stand in the fight against Ebola -- and what should be done now?

1 Dec 2014

Phenotyping human diseases in mice: an interview with Professor Carola Vinuesa

One of the main obstacles to finding effective therapies for human diseases has been our limited understanding of disease pathogenesis: we lack detailed knowledge of the cellular and molecular mechanisms that lead to the development of disease.

30 Nov 2014

Grand Challenges Canada announces $1.2 million in grant for 11 new global health innovations

Grand Challenges Canada, funded by the Government of Canada, today announced $1.2 million in funding for 11 new global health innovations implemented in member states of La Francophonie.

29 Nov 2014

Ansell launches #UniteToFightHIV campaign to raise awareness for World AIDS Day

Ansell, a global leader in protection solutions and the makers of LifeStyles Condoms, one of the nation's leading condom brands, today announced the launch of the #UniteToFightHIV, a social media campaign in partnership with the AIDS Healthcare Foundation to raise awareness for World AIDS Day on December 1, 2014.

29 Nov 2014

Certain mosquito species genetically better at transmitting malaria

Certain species of mosquitoes are genetically better at transmitting malaria than even some of their close cousins, according to a multi-institutional team of researchers including Virginia Tech scientists.

28 Nov 2014

Researchers use mathematical models to predict how immune cells respond to disease

Walter and Eliza Hall Institute researchers have defined for the first time how the size of the immune response is controlled, using mathematical models to predict how powerfully immune cells respond to infection and disease.

28 Nov 2014

Study provides proof of concept for developing antibodies against human pathogens

Scientists investigating the potentially deadly hantavirus have used a novel approach to developing protective antibodies against it. Their work, published in today's online edition of Science Translational Medicine, provides proof of concept for producing antibodies against a broad range of human pathogens.

28 Nov 2014

Ebola vaccine shows promising results in human trial

An experimental vaccine against the Ebola virus has proved effective and well-tolerated in the first human trial of a candidate Ebola drug.

27 Nov 2014

Therapeutic nanoparticle safe, effective against H. pylori infection, shows study

The bacterium Helicobacter pylori is strongly associated with gastric ulcers and cancer. To combat the infection, researchers at University of California, San Diego School of Medicine and Jacobs School of Engineering developed LipoLLA, a therapeutic nanoparticle that contains linolenic acid, a component in vegetable oils.

27 Nov 2014

Experimental Ebola vaccine appears safe, produces immune system responses in NIH phase 1 trial

An experimental vaccine to prevent Ebola virus disease was well-tolerated and produced immune system responses in all 20 healthy adults who received it in a Phase 1 clinical trial conducted by researchers from the National Institutes of Health. The candidate vaccine, which was co-developed by the NIH's National Institute of Allergy and Infectious Diseases and GlaxoSmithKline, was tested at the NIH Clinical Center in Bethesda, Maryland.

27 Nov 2014

BWH researchers identify two-faced role of TIM-3 protein

A Brigham and Women's Hospital-led team has identified a long sought-after partner for a key immune protein, called TIM-3, that helps explain its two-faced role in the immune system -- sometimes dampening it, other times stimulating it. This newly identified partner not only sheds light on the inner workings of the immune system in diseases such as HIV, autoimmunity, and cancer, but also provides a critical path toward the development of novel treatments that target TIM-3.

26 Nov 2014

New hybrid vehicle to improve delivery of DNA vaccines is under development

Described recently in the Proceedings of the National Academy of Sciences, the technology is a biomedical advancement that could help unleash the potential of DNA vaccines, which despite two decades of research, have yet to make a significant impact in the treatment of major illnesses.

26 Nov 2014

Dry powdered measles vaccine triggers no adverse side effects in early human testing

A measles vaccine made of fine dry powder and delivered with a puff of air triggered no adverse side effects in early human testing and it is likely effective, according to a paper to be published November 28 in the journal Vaccine.

26 Nov 2014

Disease/Infection News

Antibiotic resistance: Theme for next Uppsala Health Summit

Researchers identify infection control gaps as major culprit in spread of MERS-CoV

Mylan, CAS to raise funds and awareness for people living with HIV/AIDS

SIM physicians available to speak on Ebola epidemic ahead of International Volunteer Day

Mylan enters into agreement with Gilead Sciences to manufacture, distribute Tenofovir Alafenamide

Cepheid gets FDA clearance to market Xpert Norovirus

Predictive model provides information for treating 20% of human diseases

Leading experts to discuss specific strategies to combat Ebola

Phenotyping human diseases in mice: an interview with Professor Carola Vinuesa

Grand Challenges Canada announces $1.2 million in grant for 11 new global health innovations

Ansell launches #UniteToFightHIV campaign to raise awareness for World AIDS Day

Certain mosquito species genetically better at transmitting malaria

Researchers use mathematical models to predict how immune cells respond to disease

Study provides proof of concept for developing antibodies against human pathogens

Ebola vaccine shows promising results in human trial

Therapeutic nanoparticle safe, effective against H. pylori infection, shows study

Experimental Ebola vaccine appears safe, produces immune system responses in NIH phase 1 trial

BWH researchers identify two-faced role of TIM-3 protein

New hybrid vehicle to improve delivery of DNA vaccines is under development

Dry powdered measles vaccine triggers no adverse side effects in early human testing

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News